Open Access

Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: a nation-wide cohort study in a single oncological institution

,  and   
Mar 19, 2025

Cite
Download Cover

Figure 1.

The Kaplan-Meier estimated mean survival time after surgical resection.
The Kaplan-Meier estimated mean survival time after surgical resection.

Cox regression analysis of patient survival for the subcohort of 32 patients with metastases, stratified into histopathological groups according to the 2013-SPRING survival prediction model

B SE Exp(B) 95 % CI for Exp(B) p-value
Lower Upper
Age [per year] 0.039 0.037 1.040 0.967 1.119 0.293
Gender [male = 1] 0.235 0.622 1.265 0.373 4.285 0.706
Slow-growing-mets (reference) 0.022*
Fast-growing mets 1.859 0.898 6.419 1.105 37.294 0.038*
Moderate-growing mets 0.436 1.014 1.547 0.212 11.289 0.667
Pathological fx or > 1 mets -0.683 0.725 0.505 0.122 2.093 0.346
C-reactive protein [mg/L] 0.018 0.008 1.018 1.003 1.034 0.021*
Leukocyte count [109/L] 0.096 0.081 1.100 0.940 1.289 0.234
Hemoglobin [g/L] 0.027 0.029 1.027 0.971 1.087 0.348
Thrombocyte count [109/L] 0.000 0.005 1.000 0.989 1.011 0.980

Demographic characteristics, oncological stage and observed survival of patients stratified according to the histopathological diagnosis according to the 2013-SPRING survival prediction model

Fast-growing metastases Moderate-growing metastases Slow-growing metastases Sarcomas Non-oncological patients
No. of subjects 12 11 9 73 39
Mean age [years] 63 ± 14 65 ± 10 64 ± 12 42 ± 21 53 ± 19
Gender [Female/Male] 6 / 6 2 / 9 8 / 1 39 / 34 20 / 19
Percentage of patients with pathological fracture or > 1 metastasis 75% 73% 44% 18% 0%
Patients alive 2 years after the operation 25% 55% 88% 80% 100%
Patients alive 5 years after the operation 10% 30% 83% 69% 97%
Implant removed within 2 years after the operation 0% 9% 13% 9% 11%
Implant removed within 5 years after the operation 10% 10% 17% 18% 19%

Cox regression analysis of patient survival for the cohort of 144 patients with tumor endoprosthetic reconstructions, stratified into histopathological groups according to the 2013-SPRING survival prediction model

B SE Exp(B) 95 % CI for Exp(B) p-value
Lower Upper
Age [per year] 0.021 0.010 1.021 1.002 1.041 0.031*
Gender [male = 1] -0.410 0.304 0.664 0.366 1.205 0.178
Slow-growing-mets (reference) 0.002*
Fast-growing mets 1.709 0.674 5.522 1.473 20.703 0.011*
Moderate-growing mets 0.853 0.703 2.347 0.592 9.308 0.225
Sarcomas 0.831 0.661 2.296 0.629 8.378 0.208
Non-oncological patients -1.315 0.964 0.269 0.041 1.776 0.173
Pathological fx or > 1 mets 1.032 0.350 2.809 1.414 5.587 0.003*
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology